CSL787 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Noncystic Fibrosis Bronchiectasis (NCFB)
Conditions
Noncystic Fibrosis Bronchiectasis (NCFB)
Trial Timeline
Dec 7, 2020 → Mar 12, 2023
NCT ID
NCT04643587About CSL787 + Placebo
CSL787 + Placebo is a phase 1 stage product being developed by CSL for Noncystic Fibrosis Bronchiectasis (NCFB). The current trial status is completed. This product is registered under clinical trial identifier NCT04643587. Target conditions include Noncystic Fibrosis Bronchiectasis (NCFB).
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07048262 | Phase 2 | Recruiting |
| NCT04643587 | Phase 1 | Completed |